Jim Heppell, BSc, LLP

Jim was co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds successful technology, life science and clean technology companies. Jim’s first fund, the Advantage Life Sciences I Fund, won the Canadian Venture Capital Deal of the Year Award in 2006 for having the highest realized return (23.4x its investment in Aspreva Pharmaceuticals). Early in his career, Jim practiced corporate securities law with Fasken Martineau DuMoulin, one of Canada’s leading law firms. Jim then became President and CEO of Catalyst Corporate Finance Lawyers, a boutique corporate finance law firm for life science and tech companies. During his career, Jim has helped build a number of successful life science companies, including Aspreva Pharamaceuticals (acquired by Galenica Ltd. SW: GALN), Immgenics (acquired by Amgen NASDAQ: AMGN), Inovio Pharmaceuticals (NASDAQ: INO), and Sophiris Bio Inc. (NASDAW: SPHS).

He has a BSc in Microbiology and a law degree from the University of British Columbia.